European Journal of Cancer
Volume 36, Issue 16 , Pages 2061-2068 , October 2000

Ovarian cancer: an institutional review of patterns of care, health insurance and prognosis

  • S Balli

      Affiliations

    • Institute of Medical Oncology, University of Bern, Inselspital, CH-3010 Bern, Switzerland
    • ,
  • M.F Fey

      Affiliations

    • Institute of Medical Oncology, University of Bern, Inselspital, CH-3010 Bern, Switzerland
    • ,
  • W Hänggi

      Affiliations

    • Department of Gynaecology and Obstetrics, University of Bern, Inselspital, CH-3010 Bern, Switzerland
    • ,
  • D Zwahlen

      Affiliations

    • Institute of Medical Oncology, University of Bern, Inselspital, CH-3010 Bern, Switzerland
    • ,
  • G Berclaz

      Affiliations

    • Department of Gynaecology and Obstetrics, University of Bern, Inselspital, CH-3010 Bern, Switzerland
    • ,
  • E Dreher

      Affiliations

    • Department of Gynaecology and Obstetrics, University of Bern, Inselspital, CH-3010 Bern, Switzerland
    • ,
  • S Aebi

      Affiliations

    • Institute of Medical Oncology, University of Bern, Inselspital, CH-3010 Bern, Switzerland
    • Corresponding Author InformationCorresponding author. Tel.: +41-31-632-4114; fax: +41-31-382-1237

Received 17 February 2000 ,Revised 10 May 2000 ,Accepted 29 June 2000.

References 

  1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer Statistics, 1999. CA Cancer J. Clin. 1999;49:8–31
  2. Schüler G, Bopp M. C14. Ovar und Adnexe. ICD 183. Atlas der Krebsmortalität in der Schweiz C. Basel, Birkhäuser, 1997, 151–154.
  3. Boente MP, Chi DS, Hoskins WJ. The role of surgery in the management of ovarian cancer (primary and interval cytoreductive surgery). Semin. Oncol. 1998;25:326–334
  4. Eisenkop SM, Spirtos NM, Montag TW, Nalick RH, Wang HJ. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol. Oncol. 1992;47:203–209
  5. McGuire WP, Hoskins WJ, Brady ME, et al.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 1996;334:1–6
  6. Cella DF, Orav EJ, Kornblith AB, et al.  Socioeconomic status and cancer survival. J. Clin. Oncol. 1991;9:1500–1509
  7. Anonymous. Krankenversicherung. Schweizerische Sozialversicherungsstatistik. Bern, Bundesamt für Sozialversicherung, 1999, 107–120.
  8. Anonymous. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, World Health Organization, 1979.
  9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J. Am. Statist. Assoc. 1958;53:457–481
  10. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 1966;50:163–170
  11. Cox DR. Regression models and life-tables. J.R. Stat. Soc. B. (Methodology). 1972;34:187–220
  12. Junor EJ, Hole DJ, McNulty L, Mason M, Young J. Specialist gynaecologists and survival outcome in ovarian cancer (a Scottish national study of 1866 patients). Br. J. Obstet. Gynaecol. 1999;106:1130–1136
  13. ICON Collaborators . ICON2 (randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study). Lancet. 1998;352:1571–1576
  14. Friedlander ML. Prognostic factors in ovarian cancer. Semin. Oncol. 1998;25:305–314
  15. Franks P, Clancy CM, Gold MR. Health insurance and mortality. Evidence from a national cohort. J. Am. Med. Assoc. 1993;270:737–741
  16. Bush RA, Langer RD. The effects of insurance coverage and ethnicity on mammography utilization in a postmenopausal population. West. J. Med. 1998;168:236–240
  17. Alberts DS, Dahlberg S, Green SJ, et al.  Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin–cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study. Cancer. 1993;71:618–627
  18. Ayanian JZ, Kohler BA, Abe T, Epstein AM. The relation between health insurance coverage and clinical outcomes among women with breast cancer. N. Engl. J. Med. 1993;329:326–331
  19. Roetzheim RG, Pal N, Tennant C, et al.  Effects of health insurance and race on early detection of cancer. J. Natl. Cancer Inst. 1999;91:1409–1415
  20. Wannamethee SG, Shaper AG. Socioeconomic status within social class and mortality (a prospective study in middle-aged British men). Int. J. Epidemiol. 1997;26:532–541
  21. Boyd C, Zhan-Salomons JY, Groome PA, Mackillop WJ. Associations between community income and cancer survival in Ontario, Canada, and the United States. J. Clin. Oncol. 1999;17:2244–2255
  22. Anderson P. Study demonstrates link between cancer survival and wealth. Br. Med. J. 1999;318:1163
  23. Vernon SW, Heckel V, Jackson GL. Medical outcomes of care for breast cancer among health maintenance organization and fee-for-service patients. Clin. Cancer Res. 1995;1:179–184

PII: S0959-8049(00)00193-3

European Journal of Cancer
Volume 36, Issue 16 , Pages 2061-2068 , October 2000

Article Tools

* Image Usage & Resolution